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Cyclooxygenase-2 (COX-2) inhibition limits abnormal COX-2
expression and progressive injury in the remnant kidney.
Background. The pathogenesis of progressive nephropathies
involves hemodynamic and inflammatory factors. In the 5/6
nephrectomy model, a selective increase of cyclooxygenase-
2 (COX-2) expression was shown, whereas treatment with a
nonsteroidal anti-inflammatory or a specific COX-2 inhibitor
was renoprotective. We investigated in the 5/6 nephrectomy
model (1) the renal distribution of COX-2; (2) the hemodynamic
and cellular mechanisms by which chronic COX-2 inhibition
prevents renal injury.
Methods. After 5/6 nephrectomy, adult male Munich-Wistar
rats were subdivided in two groups: 5/6 nephrectomy (N =
20), receiving vehicle, and 5/6 nephrectomy + celecoxib (N =
19), treated orally with the COX-2 inhibitor, celecoxib, 10 mg/
kg/day. Untreated and treated (celecoxib) sham-operated rats
were also studied. Renal hemodynamics were examined at
4 weeks, whereas renal morphologic/immunohistochemical
studies were carried at 8 weeks.
Results. At 4 weeks, 5/6 nephrectomy rats exhibited marked
systemic and glomerular hypertension. Celecoxib attenuated
both systemic and glomerular hypertension, without affecting
glomerular filtration rate (GFR). At 8 weeks, glomeruloscle-
rosis and interstitial expansion were evident in 5/6 nephrec-
tomy rats, and markedly attenuated in 5/6 nephrectomy rats
given celecoxib. In both sham-operated and 5/6 nephrectomy
rats, COX-2 was expressed at the macula densa. The extent of
COX-2 expression at the macula densa was nearly tripled by
celecoxib, indicating the existence of a feedback mechanism. In
5/6 nephrectomy rats, COX-2 was also expressed in glomeruli,
arterioles, and the cortical interstitium, mostly at inflamed or
sclerosing areas. Celecoxib markedly attenuated renal injury,
inflammation, and ectopic COX-2 expression in 5/6 nephrec-
tomy rats.
Conclusion. Chronic COX-2 inhibition attenuated progres-
sive nephropathy by reducing glomerular hypertension, renal
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inflammation, and ectopic COX-2 expression, indicating a com-
plex contribution of COX-2 to progressive renal injury in 5/6
nephrectomy rats.
Glomerular mechanical stress caused by capillary hy-
pertension has been pointed out as a prominent factor in
the pathogenesis of chronic progressive nephropathies
[1]. In addition, evidence obtained in the past decade
indicates that progression to advanced renal fibrosis re-
quires the participation of inflammatory events such as
macrophage infiltration [2, 3], fibroblast proliferation [4],
and excessive production of extracellular matrix [5]. The
development of inflammatory processes requires a com-
plex chain of cellular events that include proliferation
of lymphocytes and monocytes, the synthesis of signal-
ing compounds such as cytokines and chemokines, the
release of growth factors, and the expression of adhesion
molecules. Vasoactive compounds, such as angiotensin II
[6], endothelin [7] and prostanoids [8], can also act as in-
flammatory agents, and mediate renal injury, in chronic
nephropathies.
Cyclooxygenase (COX) derivatives have long been
known to participate in a variety of inflammatory dis-
eases that affect several tissues [9–12]. Accordingly, up-
regulation of the COX-1 and/or the COX-2 isoforms has
been described in several clinical and experimental con-
ditions characterized by inflammation [13–15]. Of note,
COX-2 up-regulation was also found in experimental
glomerulonephritis [16, 17] and in the Fawn-Hooded rat
[18], a model of progressive glomerulosclerosis. In the re-
nal ablation model (5/6 nephrectomy), an increase in the
renal expression of COX-2 in the macula densa, and to a
lesser extent in the glomerulus, was observed at 2 weeks,
before the appearance of significant structural injury
[19].
Consistent with the evidence implicating COX deriva-
tives in the pathogenesis of progressive nephropathies,
chronic treatment with a gastric-sparing nonsteroidal
anti-inflammatory drug markedly attenuated renal injury
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in the 5/6 nephrectomy model [20]. Since only numerical
reduction of glomerular pressure was obtained with the
compound, the protective effect that was observed must
be credited mostly to its anti-inflammatory properties.
Renal protection was also obtained with a specific COX-2
inhibitor in 5/6 nephrectomy rats [21] and in mice with
lupus nephropathy [22], suggesting that COX-2–derived
prostanoids can mediate the renal injury associated with
these models.
In the present study, we examined the renal immuno-
histochemical expression of COX-2 60 days after renal
mass removal, when glomerular, vascular and interstitial
lesions are fully established in this model. In addition,
we assessed the effect of celecoxib, a selective COX-2 in-
hibitor, on the renal expression of COX-2, and whether a
possible renoprotective effect of celecoxib would involve
a glomerular hemodynamic effect, an anti-inflammatory
effect, or both.
METHODS
We used 72 adult male Munich-Wistar rats obtained
from a local colony and weighing initially 240 to 260 g.
All rats received food (22% protein) and tap water ad
libitum, and were kept under a 12-hour light/12-hour
dark cycle. All experimental procedures were in strict
accordance with our institutional guidelines and with in-
ternational standards for manipulation and care of ani-
mals, and were previously approved by the local Research
Ethics Committee.
To perform 5/6 reduction of renal mass (5/6 nephrec-
tomy), rats were subjected to a ventral laparotomy un-
der anesthesia with sodium pentobarbital, 50 mg/kg,
intraperitoneally. The right kidney was surgically re-
moved, whereas the left kidney underwent infarction of
nearly two-thirds of its mass by ligation of the appropri-
ate renal artery branches. Sham-operated rats were sub-
jected to anesthesia and laparotomy as described above.
However, only manipulation of the renal pedicles, with-
out any renal mass removal, was performed in these
animals.
Experimental groups
Four experimental groups were studied: (1) sham-
operated rats (N = 15); (2) sham-operated rats treated
orally with celecoxib, 10 mg/kg/day (this was the max-
imal dose not promoting growth stunting0 (N = 17);
(3) rats subjected to 5/6 nephrectomy and given vehicle
only (N = 20); and (4) rats subjected to 5/6 nephrectomy
and treated with celecoxib as above (N = 19). Celecoxib
was dissolved in a mixture of 5% dimethylsulfoxide and
olive oil and given daily by gavage, starting 1 day after
surgery. Untreated rats (sham-operated and 5/6 nephrec-
tomy groups) received vehicle only.
Renal hemodynamic studies
Thirty days after renal ablation, rats from sham-
operated (N = 7), sham-operated given celecoxib (N =
7), 5/6 nephrectomy (N = 8), and 5/6 nephrectomy given
celecoxib (N = 8) were anesthetized with Inactin, 100 mg/
kg, intraperitoneally, and prepared for whole kidney and
glomerular hemodynamic studies to determine mean ar-
terial pressure (MAP), glomerular filtration rate (GFR),
renal plasma flow (RPF), renal vascular resistance
(RVR), and glomerular hydraulic pressure (PGC). The
details of the experimental procedures adopted in these
studies are given elsewhere [20].
Long-term studies
Eight rats from the sham-operated group, 10 from the
sham-operated given celecoxib group, 10 from the 5/6
nephrectomy group, and 11 from the 5/6 nephrectomy
given celecoxib were followed up to 60 days after surgery.
At 30 days, tail-cuff pressure (TCP) and the daily ex-
cretion rate of albumin (UalbV) were determined. These
measurements were repeated at 60 days, along with the
daily urinary excretion rate of prostaglandin E2 (PGE2)
and thromboxane B2 (TxB2), an inactive metabolite of
thromboxane A2. A small (50 lL) blood sample was
drawn from a tail vein and immediately chilled for sub-
sequent determination of plasma renin activity (PRA).
The rats were thereafter anesthetized with sodium pento-
barbital, 50 mg/kg, intraperitoneally, and a blood sample
was collected from the abdominal aorta for determina-
tion of serum creatinine concentration. The kidneys were
then perfusion-fixed with Duboscq-Brazil solution after
a brief washout with saline. After fixation, the renal tissue
was weighed and two midcoronal sections were postfixed
in buffered 4% formaldehyde. The material was then
embedded in paraffin for assessment of glomerular, in-
terstitial, and vascular injury, as well as for immunohisto-
chemical analysis.
Histomorphometry
All morphometric evaluations were performed in a
blinded manner by a single observer in sections 2 to 3 lm
thick. The extent of glomerulosclerosis (GS) was evalu-
ated, in sections stained with periodic acid-Schiff (PAS),
by attributing to each glomerulus a score that reflected
the fraction of the tuft area taken by the sclerosing injury,
as described previously [20]. A GS index (GSI) was calcu-
lated for each rat as the weighted average of the individ-
ual glomerular scores obtained in this manner multiplied
by 100. At least 120 glomeruli were examined for each
rat. To assess the severity of interstitial expansion, the
percentage of the renal cortical area occupied by intersti-
tial tissue (%INT) was estimated in Masson-stained sec-
tions by a point counting technique [23] in 25 consecutive
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microscopic fields, at a final magnification of 100×, under
a 176-point grid. The extent of vascular injury was ex-
pressed by the percentage of vessels exhibiting wall injury
per 100 vascular profiles examined (%VASC).
Immunohistochemical analysis
ED-1 and COX-2 were detected in 4 lm thick paraffin-
embedded sections. Sections were mounted on glass
slides coated with 2% gelatin, deparaffinized in xylene
and rehydrated through graded ethanol and in distilled
water as the final step. Sections were then subjected to
microwave irradiation in citrate buffer to enhance anti-
gen retrieval and preincubated with 5% normal rabbit
(for ED-1) or horse (for COX-2) serum in Tris-buffered
saline (TBS), to prevent nonspecific protein binding.
Negative control experiments for all antigens were per-
formed by omitting incubation with the primary antibody.
For immunohistochemical detection of macrophages,
a monoclonal mouse antirat ED-1 antibody (Serotec,
Oxford, UK) was used. The incubations were carried
out overnight at 4◦C in a humidified chamber. Af-
ter washing, the sections were incubated with rab-
bit antimouse immunoglobulins (Dako Co., Glostrup,
Denmark). To complete the sandwich technique, in-
cubation with a soluble complex of alkaline phos-
phatase antialkaline phosphatase (APAAP) Dako Co.)
was performed. Sections were then incubated with a
freshly prepared substrate, consisting of naphthol AS-
MX-Phosphate (Sigma Chemical Co., St. Louis, MO,
USA) and fast red dye (Sigma Chemical Co), coun-
terstained with Mayer’s hemalaum and covered with
Kaiser’s glycerin-gelatin (Merck, Darmstadt, Germany).
For specific immunostaining of COX-2, a monoclonal
mouse antirat COX-2 antibody (Transduction Laborato-
ries, Lexington, KY, USA) and an indirect streptavidin-
biotin alkaline phosphatase technique were used.
Sections were preincubated overnight at 4◦C in a humid-
ified chamber with avidin and biotin solutions to block
nonspecific binding of these compounds. Sections were
then incubated with rat-adsorbed biotinylated antimouse
IgG (Vector Labs, Burlingame, CA, USA) for 45 minutes
at room temperature, followed by incubation with the
streptavidin-biotin-alkaline phosphatase complex (Dako
Co.) for 30 minutes at room temperature [24]. Sections
were then developed as described above.
Quantitative analysis of ED-1–positive cells was per-
formed in a blinded fashion by a single observer under
250× magnification and expressed as positively stained
cells (+cells)/mm2. For each section, 25 microscopic
fields, each corresponding to an area of 0.06 mm2, were
examined.
The renal expression of COX-2 was quantified in
the following manners: cells expressing COX-2 at the
glomerular tufts were counted individually, and the re-
sults expressed as + cells/100 glomerular cross-sections
(gcs). In the cortical interstitium, the intensity of COX-
2 staining was expressed as + cells/mm2. The vascular
expression of COX-2 was given as + cells/100 vascular
profiles. The expression of COX-2 at the macula densa
was quantified by counting the number of macula densas
staining positively for COX-2, and expressing the result
in macula densa+ per 100 gcs.
Analytic techniques
Urinary albumin excretion rate was determined by
conventional radial immunodiffusion. Total plasma pro-
tein concentration was determined by refractometry.
Serum creatinine concentration was assessed using a col-
orimetric method. Urinary PGE2 and TxB2 excretion
rates and PRA were assessed by radioimmunoassay, us-
ing commercially available kits (New England Nuclear
Life Sciences Products, Boston, MA, USA).
Statistics
One-way analysis of variance (ANOVA) with pair-wise
comparisons, according to the Bonferroni method [25],
was used to assess differences among groups. The Spear-
man correlation coefficient was determined to evaluate
the existence of significant linear correlation between pa-
rameters obtained in individual rats. Since GSI and albu-
min excretion rates were not normally distributed, log
transformations were performed prior to statistical anal-
ysis of these parameters. For the same reason, arcsine
transformation was required before analysis of%INT
[26]. P levels of 0.05 or less were considered significant.
RESULTS
Renal hemodynamic studies (30 days of ablation)
Body weights were lower in both 5/6 nephrectomy
and 5/6 nephrectomy given celecoxib groups compared
with the respective sham-operated values (Table 1). Cele-
coxib treatment promoted no further limitation of body
growth. MAP was elevated in the 5/6 nephrectomy group
(147 ± 5 mm Hg vs. 107 ± 2 mm Hg in sham-operated,
P < 0.05). Treatment with celecoxib reduced MAP in
5/6 nephrectomy group given celecoxib, although values
remained significantly higher compared to the respec-
tive sham-operated group (135 ± 3 mm Hg, P < 0.05
vs. sham-operated given celecoxib and 5/6 nephrectomy
groups). Kidney weights were significantly lower in the
5/6 nephrectomy group than in the sham-operated group
(1.3 ± 0.07 g vs. 1.5 ± 0.02 g, respectively, P < 0.05) and
were unchanged by celecoxib treatment (P > 0.05 vs.
5/6 nephrectomy). In remnant kidneys, GFR was ∼50%
lower in the 5/6 nephrectomy group compared with the
sham-operated group (0.61 ± 0.1 mL/min, P < 0.05),
and was unaffected by celecoxib (0.65 ± 0.1 mL/min in
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Table 1. Renal and systemic functional and hemodynamic parameters 30 days after 5/6 nephrectomy
Body Left kidney Mean arterial Glomerular filtration Renal plasma PGC Renal vascular resistance
weight g weight g pressure mm Hg rate mL/min flow mL/min mm Hg mm Hg/mL/min
Sham 307 ± 3 1.5 ± 0.1 107 ± 2 1.30 ± 0.04 4.1 ± 0.2 52 ± 1 14 ± 1
Sham+ celecoxib 304 ± 6 1.6 ± 0.1 114 ± 2 1.30 ± 0.05 3.9 ± 0.3 54 ± 1 16 ± 1
5/6 nephrectomy 264 ± 8a 1.3 ± 0.1a 147 ± 5a 0.61 ± 0.10a 1.9 ± 0.3a 68 ± 2a 57 ± 10a
5/6 nephrectomy + 267 ± 5a 1.4 ± 0.1a 135 ± 3a,b 0.65 ± 0.10a 2.2 ± 0.2a 60 ± 2a,b 40 ± 5a
celecoxib
PGC is glomerular hydraulic pressure. Results are expressed as mean ± 1 SE.
aP < 0.05 vs. respective sham-operated group; bP < 0.05 vs. respective untreated group.
Table 2. Renal and systemic functional parameters 60 days after 5/6 nephrectomy
Body Tail-cuff Urinary albumin Serum creatinine Urinary PGE2 excretion UrinaryTxB2 excretion
weight g pressure mm Hg excretion mg/24 hours mg/dL rate ng/24 hours rate ng/24 hours
Sham (N = 10) 333 ± 8 116 ± 2 2.5 ± 0.3 0.5 ± 0.1 162 ± 13 17 ± 1
Sham + celecoxib 320 ± 3 121 ± 3 1.5 ± 0.3 0.5 ± 0.1 157 ± 20 17 ± 1
(N = 10)
5/6 nephrectomy 278 ± 5a 198 ± 5a 78 ± 9a 0.9 ± 0.1a 46 ± 9a 22 ± 2a
(N = 12)
5/6 nephrectomy + 279 ± 7a 186 ± 9a 50 ± 7a,b 0.8 ± 0.1a,b 24 ± 4a 14 ± 1b
celecoxib (N = 11)
Abbreviations are: TxB2, thromboxane B2; PGE2, prostaglandin E2. Results are expressed as mean ± 1 SE.
aP < 0.05 vs. respective sham-operated group; bP < 0.05 vs. respective untreated group.
5/6 nephrectomy group given celecoxib, P > 0.05 vs. 5/6
nephrectomy group). Likewise, RPF was ∼50% lower
than in the sham-operated group (1.9 ± 0.3 mL/min in the
5/6 nephrectomy group vs. 4.1 ± 0.20 mL/min in sham-
operated group, P < 0.05), and was unchanged by cele-
coxib (2.2 ± 0.2 mL/min in 5/6 nephrectomy group given
celecoxib vs. 5/6 nephrectomy group, P > 0.05). RVR in-
creased in 5/6 nephrectomy rats (57 ± 10 mm Hg/mL/min,
P < 0.05 vs. sham-operated group), and was numerically
decreased by celecoxib treatment (40 ± 5 mm Hg/mL/min
in 5/6 nephrectomy rats given celecoxib, P > 0.05 vs. 5/6
nephrectomy group). PGC was markedly elevated in the
5/6 nephrectomy group (68 ± 2 mm Hg vs. 52 ± 1 mm Hg
in the sham-operated group, P < 0.05). Celecoxib treat-
ment attenuated glomerular hypertension compared with
5/6 nephrectomy, although PGC remained high relative to
sham-operated values (60 ± 2 mm Hg in 5/6 nephrectomy
group given celecoxib, P <0.05 vs. 5/6 nephrectomy group
and sham-operated group given celecoxib).
Follow up studies (60 days of ablation)
Mortality was zero in all groups (not shown). Body
weight was significantly lower in the 5/6 nephrectomy
group compared to sham-operated group (278 ± 5 g vs.
333 ± 8 g, P < 0.05), and was unchanged by celecoxib
treatment (279 ± 7 g in 5/6 nephrectomy group given cele-
coxib, P > 0.05 vs. 5/6 nephrectomy group) (Table 2). TCP
was markedly elevated in 5/6 nephrectomy rats (198 ±
5 mm Hg vs. 116 ± 2 mm Hg in sham-operated group,
P < 0.05). Treatment with celecoxib reduced numeri-
cally TCP in the 5/6 nephrectomy group given celecoxib
(186 ± 9 mm Hg, P > 0.05 vs. 5/6 nephrectomy). UalbV
was markedly increased in the 5/6 nephrectomy group rel-
ative to the sham-operated group (78 ± 9 mg/24 hours vs.
2.5 ± 0.3 mg/24 hours, P < 0.05), and significantly reduced
by celecoxib treatment (50 ± 7 mg/24 hours in the 5/6
nephrectomy group given celecoxib, P < 0.05 vs. sham-
operated group given celecoxib and vs. 5/6 nephrectomy
group). Serum creatinine was elevated in the 5/6 nephrec-
tomy group compared with sham-operated group (0.9 ±
0.03 mg/dL vs. 0.5 ± 0.02 mg/dL, P < 0.05), and slightly
but significantly reduced by celecoxib (0.8 ± 0.04 mg/dL
in 5/6 nephrectomy group given celecoxib, P < 0.05 vs.
5/6 nephrectomy group and P < 0.05 vs. sham-operated
group given celecoxib). Urinary PGE2 excretion was de-
creased in the 5/6 nephrectomy group 60 days after renal
ablation (46 ± 9 ng/day in 5/6 nephrectomy group vs.
162 ± 13 in sham-operated group, P < 0.05), in contrast
with urinary TxB2 excretion, which was increased in 5/6
nephrectomy group (22 ± 2 ng/day vs. 17 ± 1 ng/day in
sham-operated group, P < 0.05). In 5/6 nephrectomy rats,
celecoxib treatment reduced PGE2 numerically (24 ±
4 ng/day in the 5/6 nephrectomy group given celecoxib,
P < 0.05 vs. sham-operated group given celecoxib and
P > 0.05 vs. 5/6 nephrectomy group), and normalized
TxB2 excretion (14 ± 1 ng/day in 5/6 nephrectomy group
given celecoxib, P < 0.05 vs. 5/6 nephrectomy group, and
P > 0.05 vs. sham-operated group given celecoxib).
As expected, PRA was reduced in the 5/6 nephrec-
tomy group (0.82 ± 0.26 vs. 2.04 ± 0.45 in sham-operated
group, P < 0.05). Celecoxib treatment did not affect PRA
(1.53 ± 0.29 ng AI/mL/hour in the sham-operated group
given celecoxib and 0.54 ± 0.13 ng AI/mL/hour in the 5/6
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Fig. 1. Parameters of renal injury/infla-
mmation 60 days after renal ablation in sham
(S) group, sham + celecoxib (S + CEL), renal
ablation (Nx), and renal ablation + celecoxib
(Nx + CEL). (A) Glomerulosclerosis index
(GSI).(B) Fractional cortical interstitial
area (%INT). (C) Percent vascular injury
(%VASC). (D) Extent of macrophage infil-
tration (Mφ ). ∗P < 0.05 vs. respective sham
group; †P < 0.05 vs. respective untreated
group.
nephrectomy group given celecoxib, P > 0.05 vs. respec-
tive untreated).
Histomorphometric studies
Glomerular sclerotic lesions and renal interstitial ex-
pansion were evident in 5/6 nephrectomy rats 60 days af-
ter ablation. Accordingly, the GSI (Fig. 1A) was markedly
increased in the 5/6 nephrectomy group (47 ± 14 vs. 0.3 ±
0.1 in sham-operated group, P < 0.05). Treatment with
celecoxib reduced GSI, although values remained signif-
icantly higher in the 5/6 nephrectomy group given cele-
coxib than in sham-operated group given celecoxib (19 ±
6, P < 0.05 vs. sham-operated group and 5/6 nephrec-
tomy group). Likewise, marked interstitial expansion, as
assessed by%INT (Fig. 1B) was observed in 5/6 nephrec-
tomy rats (6.3% ± 0.4% in the 5/6 nephrectomy group
vs. 0.2% ± 0.05% in the sham-operated group, P < 0.05).
Treatment with celecoxib significantly reduced%INT in
the 5/6 nephrectomy group given celecoxib compared to
5/6 nephrectomy group (3.8% ± 1.1%, P < 0.05 vs. 5/6
nephrectomy and sham-operated groups). Vascular in-
jury was seen mostly in arterioles and a few arteries, and
was represented by intimal hypertrophy and medial hy-
perplasia, the latter frequently taking an “onion skin”
aspect. Only few, scattered areas of fibrinoid necrosis
were observed. The percent of vessels exhibiting these
lesions (%VASC) (Fig. 1C) was markedly increased in
5/6 nephrectomy rats (5.9 ± 1.2 vs. 0.1 ± 0.1 in sham-
operated group, P < 0.01), and significantly attenuated
by celecoxib treatment (2.5 ± 1.8 in sham-operated rats
given celecoxib, P < 0.05).
Immunohistochemistry
The expression of the macrophage-specific ED-1 anti-
gen (Fig. 1D) was markedly increased in 5/6 nephrectomy
rats at day 60 (113 ± 18 cells/mm2 in 5/6 nephrectomy
group vs. 30 ± 4 cells/mm2 in sham-operated rats, P <
0.05). Celecoxib treatment limited the number of ED-1–
positive cells in the 5/6 nephrectomy group given cele-
coxib, although values remained significantly higher in
5/6 nephrectomy group given celecoxib compared with
sham-operated rats given celecoxib (80 ± 11 cells/mm2
in 5/6 nephrectomy group given celecoxib, P < 0.05
vs. 5/6 nephrectomy and sham-operated given celecoxib
groups).
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Fig. 2. Cyclooxygenase-2 (COX-2) expres-
sion followed four typical patterns in this
study (positive cells appear heavily stained).
(A) Macula densa staining observed in all
groups. (B) Glomerular infiltration by COX-
2–positive cells. Note that in this case the in-
filtration concentrated at a sclerosing area.
(C) Interstitial infiltration by COX-2–positive
cells, appearing mostly in inflamed areas.
(D) Infiltration of arterial/arteriolar walls by
COX-2–positive cells, following an “onion
skin” pattern. Patterns exemplified in (B, C,
and D) appeared only in renal ablation group
and, to a lesser extent, in the renal ablation
group given celecoxib.
As described previously [19], COX-2 was clearly visible
in the macula densa region of sham-operated rats, indicat-
ing that this isoform is constitutively expressed (Fig. 2A).
COX-2 expression was also seen in tubular epithelial
cells outside the macula densa, especially at the collect-
ing ducts. The intensity of COX-2 expression at this latter
location did not vary among groups (not shown). COX-
2 expression was scanty elsewhere in the renal tissue of
sham-operated rats. In 5/6 nephrectomy rats, COX-2 was
similarly expressed at the macula densa region. In addi-
tion, COX-2 appeared in glomeruli (Fig. 2B), inflamed
interstitial areas (Fig. 2C) and arterial/arteriolar walls. In
the latter, COX-2–positive cells acquired an “onion skin”
aspect similar to that observed in severely damaged ves-
sels under light microscopy (Fig. 2D). Quantitative eval-
uation of this “ectopic” COX-2 expression is shown in
Figure 3. The expression of COX-2 at the macula densa
(Fig. 3A) was numerically increased in the 5/6 nephrec-
tomy group compared to the sham-operated group (8.4 ±
1.4 macula densa–positive/100 gcs vs. 6.9 ± 1.6 macula
densa–positive/100 gcs in sham-operated rats, P > 0.05).
Of note, celecoxib treatment markedly increased the ex-
pression of COX-2 at the macula densa, an effect ob-
served in both sham-operated and 5/6 nephrectomy rats
(Fig. 3A). The glomerular expression of COX-2 (Fig. 3B)
was dramatically increased in the 5/6 nephrectomy group
(11.4 ± 3.5 cells/100 gcs vs. 0.1 ± 0.1 cells/gcs in sham-
operated rats, P < 0.05) and significantly attenuated by
celecoxib treatment (4.6 ± 3.6 cells/100 gcs in 5/6 nephrec-
tomy group given celecoxib, P < 0.05 vs. 5/6 nephrectomy
group and P > 0.05 vs. sham-operated rats given cele-
coxib) (Fig. 3B). Celecoxib treatment also significantly
reduced COX-2 expression in the renal interstitium (3.1±
1.1 cells/mm2 in 5/6 nephrectomy group given celecoxib
vs. 4.7 ± 1.5 cells/mm2 in 5/6 nephrectomy group, P <
0.05), and in arteries/arterioles (4.8 ± 3.5 cells/100 ves-
sels in 5/6 nephrectomy group given celecoxib vs. 20.2 ±
5.1 cells/100 vessels in 5/6 nephrectomy group, P < 0.05).
A significant linear correlation was shown between the
indices of glomerular, interstitial, and vascular injury and
the respective intensity of COX-2 expression at each of
these compartments (Fig. 4). By contrast, no correlation
was seen between the extent of glomerular, interstitial,
or vascular injury and the expression of COX-2 at the
macula densa (data not shown).
DISCUSSION
As shown in previous studies [3, 19, 20], untreated 5/6
nephrectomy rats exhibited systemic and glomerular hy-
pertension and, 60 days after renal ablation, massive al-
buminuria, renal macrophage infiltration, advanced GS,
and renal interstitial expansion. Renal vascular injury
of apparent hypertensive origin, consisting mostly of
intimal hyalinosis and moderate medial proliferation,
was also easily observed. The hemodynamic derange-
ment observed in 5/6 nephrectomy rats likely exerted a
pathogenic role: while arterial hypertension can explain
most of the vascular lesions appearing in 5/6 nephrec-
tomy rats, glomerular hypertension is thought to initiate
a chain of events that culminates in focal and segmental
GS and leads to glomerular obsolescence [1]. In addition,
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Fig. 3. Graphic representation of the expres-
sion of cyclooxygenase-2 (COX-2) at the mac-
ula densa (A), glomeruli (B), interstitial area
(C) and arteries/arterioles (D) in the four
groups studied. ∗P < 0.05 vs. respective sham
group; †P < 0.05 vs. respective untreated
group. Abbreviations are: S, sham group;
S + CEL, sham + celecoxib; Nx, renal ab-
lation, and Nx + CEL, renal ablation + cele-
coxib.
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Fig. 4. Parameters of renal injury represented as a function of cyclooxygenase-2 (COX-2) expression. The extent of injury at the glomeruli, cortical
interstitium, and vessels correlated positively and significantly with the respective “ectopic” expression of COX-2, but not with the expression
of COX-2 at the macula densa (data not shown). (A) Glomerulosclerosis index (GSI) vs. the intensity of COX-2 staining at the glomerular tuft
(expressed as stained cells/100 glomerular profiles). (B) Fraction of the cortical area occupied by interstitial matrix (%INT) vs. the intensity of
COX-2 staining at the interstitium (expressed as stained cells/mm2). (C) Percent of arterial/arteriolar profiles exhibiting wall injury (%VASC) vs.
intensity of COX-2 staining at the vessels (expressed as stained cells/100 vascular profiles).
the presence of inflammation, indicated in this study by
the intense macrophage infiltration observed in remnant
kidneys, is believed to participate decisively in the propa-
gation of renal injury, initiated by either mechanical strain
or by nonhemodynamic factors such as massive protein
filtration [2, 3, 27, 28].
Previous evidence suggested that prostanoid produc-
tion is enhanced in 5/6 nephrectomy rats, and that these
compounds are involved in the pathogenesis of renal in-
jury in this model [19–21, 29–33]. In the present study,
the urinary excretion of PGE2 was markedly decreased
in 5/6 nephrectomy rats compared to sham-operated rats,
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in agreement with previous observations in this model
[29]. Since urinary PGE2 excretion fell roughly in propor-
tion with renal mass reduction, and since renal synthesis
is a major source of urinary prostanoids [29], the pro-
duction of PGE2 per remnant nephron likely remained
constant or was only modestly increased by renal abla-
tion. A different picture was seen regarding TxB2. Al-
though the basal urinary excretion rate of this prostanoid
was lower than that of PGE2, it was increased by 40% in
the 5/6 nephrectomy group, in accordance with previous
studies [29–31]. Since nephron number was drastically
reduced in this group, the synthesis of TxA2 per rem-
nant nephron must have been increased severalfold rel-
ative to the sham-operated group. Given the well-known
vasoconstrictor properties of thromboxanes, as well as
their effect on platelet aggregation and cell proliferation,
the present findings corroborate the view that these com-
pounds are particularly important mediators of chronic
progressive renal injury [30, 31].
The exact pathways leading to enhanced TxB2 synthe-
sis in the 5/6 nephrectomy model have not been elu-
cidated. However, the available evidence consistently
indicates that COX-1 up-regulation is not involved in this
process. In three independent studies of the 5/6 nephrec-
tomy model [19, 32, 33], the renal expression of COX-1
remained unchanged after either renal mass removal or
treatment with a COX-2 inhibitor, suggesting that en-
hanced expression and/or activity of the COX-2 isoform,
which is constitutively expressed at the macula densa,
was instead responsible for the increased production
of prostanoids. In the present study, the expression of
COX-2 at the macula densa was numerically increased
in the 5/6 nephrectomy group compared to the sham-
operated group, although this difference did not attain
statistical significance. Of particular interest, the expres-
sion of COX-2 at the macula densa was more than three
times as high in both sham-operated and 5/6 nephrec-
tomy rats treated with celecoxib, compared with the re-
spective untreated controls. This finding, not reported
previously, suggests that, under both physiologic and
pathophysiologic conditions, macula densa COX-2 may
be suppressed, via a negative feedback loop, by the lo-
cal levels of its own end products. The existence of such a
mechanism would suggest that the production of COX-2–
derived prostanoids at the macula densa must be closely
regulated, and reinforce the view that COX-2 exerts an
important physiologic role at this location, in all likeli-
hood related to sodium homeostasis [34].
While in sham-operated rats COX-2 was detected
almost exclusively at the macula densa, the remnant
kidneys also exhibited intense COX-2 staining at the
glomeruli, cortical interstitium, and small vessels. The
distribution pattern and the behavior of this “ectopic”
COX-2 strongly suggest its involvement in the pathogen-
esis of chronic renal injury, rather than in homeostatic
processes. In the glomeruli, COX-2 staining was heaviest
at sclerosing areas, although it was also seen at appar-
ently preserved tufts. This finding raises the possibility
that glomerular COX-2 expression might antecede GS,
since it was also described 2 weeks after renal ablation
[19], when little glomerular injury is present. At the cor-
tical interstitium, COX-2 expression was confined to in-
flamed areas. Likewise, vascular COX-2 expression was
seen almost exclusively at damaged arterioles, and might
participate in the pathogenesis of hypertensive vascular
injury. The extent of this “ectopic” COX-2 expression cor-
related significantly with the severity of all three indices
of renal damage, GSI,%INT, and%VASC, in consistency
with the hypothesis that COX-2 mediates renal injury in
this model. By contrast, none of these indices correlated
with the extent of COX-2 expression at the macula densa,
reinforcing the view that, at this location, COX-2 exerts
a physiologic, rather than pathogenic, effect. The notion
that “ectopic” COX-2 participates in the pathogenesis of
renal injury in this model, at variance with its physio-
logic role at the macula densa, is further strengthened by
the differing behavior of COX-2 expression in response
to celecoxib. As noted above, macula densa COX-2
rose with celecoxib treatment, suggesting the existence
of a physiologic feedback mechanism between COX-2
and prostanoids. By contrast, celecoxib treatment, which
exerted marked renoprotection, strongly attenuated the
expression of COX-2 at injured areas, suggesting that
here COX-2 exerted a pathogenic, rather than physio-
logic, role.
COX-2–derived prostanoids can participate in the
pathogenesis of renal inflammation and structural in-
jury in the 5/6 nephrectomy model via both hemody-
namic and nonhemodynamic mechanisms. Glomerular
hypertension resulting from preferential dilatation of
the afferent arteriole can stimulate the renal production
of a host of inflammatory mediators such as platelet-
derived growth factor (PDGF) [35], TGF-b [36, 37],
and angiotensin II (Ang II)[38]. Even the production of
prostaglandins can be enhanced by glomerular hyperten-
sion [27], which would close a positive feedback loop.
In addition, prostaglandins can participate in renal in-
flammation in a more direct fashion, since COX-2 is ex-
pressed in inflammatory cells, such as activated human
monocytes, macrophages, and T lymphocytes [39–41],
and Ang II–stimulated rat cardiac fibroblasts [42]. More-
over, thromboxanes can favor renal fibrosis by enhancing
extracellular matrix production by mesangial cells [43, 44]
and by mediating vascular smooth muscle cell prolifera-
tion [45–47]. “Cross talk” between prostanoids and other
inflammatory mediators such as Anf II and nitric oxide is
likely to intensify and further propagate the sequence of
events leading to renal fibrosis [42, 47–50]. Given the lack
of significant effect of celecoxib on circulating renin lev-
els, any pathogenic interaction between COX products
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and Ang II must have occurred at the intrarenal, rather
than systemic, level.
Treatment with celecoxib reduced the urinary ex-
cretion of both PGE2 and TxB2, and strongly attenu-
ated albuminuria and macrophage infiltration, as well as
glomerular and interstitial injury, largely confirming the
results reported by Wang et al [21] in the 5/6 nephrec-
tomy model. This beneficial effect may have resulted
from the hemodynamic effect of the drug, since PGC
was lowered from 68 to 60 mm Hg in the 5/6 nephrec-
tomy group given celecoxib. The mechanism by which
celecoxib may have attenuated glomerular hyperten-
sion in 5/6 nephrectomy is unclear. Celecoxib treatment
might have resulted in afferent vasoconstriction, since va-
sodilatory prostaglandins may contribute to maintain the
normal tonus of the afferent arteriole [51, 52] and may
mediate afferent vasodilatation in the 5/6 nephrectomy
model [53]. In addition, the possibility that celecoxib
lowered PGC through its well-known interaction with
the renin-angiotensin system cannot be excluded. Irre-
spective of the hemodynamic mechanisms involved, PGC
remained markedly elevated in 5/6 nephrectomy rats
given celecoxib compared to sham-operated rats, sug-
gesting that the protective effect of celecoxib may have
resulted, at least in part, from interference with inflamma-
tory mechanisms such as lymphocyte/macrophage pro-
liferation and deposition of extracellular matrix. This
possibility, which is consistent with the well-known anti-
inflammatory nature of COX-2 inhibitors, is reinforced
by the observation that celecoxib strongly attenuated re-
nal macrophage infiltration in 5/6 nephrectomy rats. It
should be noted that celecoxib treatment was initiated
immediately after renal mass removal, thus suppressing
any early events that might be mediated by prostanoids.
In a recent preliminary study of this laboratory, the renal
protection afforded by COX inhibition initiated at day
30, when renal injury was already established, was less
effective than previously observed with early treatment.
However, combined therapy with a COX inhibitor and
an Ang II receptor blocker conferred much better pro-
tection than with either drug alone [abstract; Goncalves
et al, J Am Soc Nephrol 12:813A, 2001]. As a whole, these
observations suggest that intrarenal pathogenic events
mediated by Ang II and prostanoids remain active even
at advanced phases of renal injury in the 5/6 nephrectomy
model.
CONCLUSION
COX-2 expression was observed at two distinct loca-
tions in the remnant kidney: a large fraction of the isoen-
zyme remained at the macula densa, while an “ectopic”
fraction was expressed at the glomeruli, cortical intersti-
tium, and damaged vessels, correlating strongly with all
indices of renal injury. Celecoxib treatment attenuated
renal injury in 5/6 nephrectomy rats by a combined effect
on glomerular hemodynamics and on renal inflammation.
As a whole, the present results indicate that abnormal
COX-2 expression has an important role in the patho-
genesis of renal injury in the 5/6 nephrectomy model.
Chronic treatment with COX-2 inhibitors may represent
a new tool in the present struggle to arrest or retard the
progression of human nephropathies. Future studies will
determine whether these compounds can indeed help to
prevent human end-stage renal disease (ESRD), and to
what extent their clinical usefulness may be limited by
their well-known untoward effects.
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